2.22
2.30%
0.05
Handel nachbörslich:
2.08
-0.14
-6.31%
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Cross Above 50-Day Moving AverageWhat's Next? - MarketBeat
Contrasting Star Equity (NASDAQ:STRR) and Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc - Yahoo Finance
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLC - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Target Price from Analysts - MarketBeat
Stonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MSN
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
Accenture (NYSE:ACN) PT Raised to $365.00 - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World
Investing in Astrazeneca plc ADR (AZN) Is Getting More Attractive - Knox Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
Metric Deep Dive: Understanding Accenture plc (ACN) Through its Ratios - The Dwinnex
American Century Companies Inc. Boosts Stock Position in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial - Clinical Trials Arena
Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily
Accel Entertainment CEO sells shares worth over $49,000 By Investing.com - Investing.com UK
Arch Capital Group (ACGL) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright - MarketBeat
Meeder Advisory Services Inc. Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - Defense World
William Blair Investment Management LLC Sells 17,390 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Arch Capital Group (NASDAQ:ACGL) Sets New 1-Year High at $114.69 - MarketBeat
(ACEL) Long Term Investment Analysis - Stock Traders Daily
Analyzing Axcelis Technologies Inc (ACLS) After Recent Trading Activity - Knox Daily
Quest Partners LLC Cuts Stake in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Financial Metrics Exploration: Understanding Acrivon Therapeutics Inc (ACRV) Through Ratios - The Dwinnex
Market Watch: Aclarion Inc (ACON)’s Noteworthy Drop, Closing at 0.18 - The Dwinnex
Citi lifts Accenture stock price target on growth prospects - Investing.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Analysts - MarketBeat
Aclaris Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis - Yahoo Finance
Quest Partners LLC Grows Position in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
Arch Capital Group (ACGL) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Accenture (ACN) Rises Higher Than Market: Key Facts - Yahoo Finance
AstraZeneca PLC ADR rises Monday, outperforms market - MarketWatch
Market Momentum: Astrazeneca plc ADR (AZN) Registers a -0.87 Decrease, Closing at 78.27 - The Dwinnex
Acrivon Therapeutics: Promising Trial Results and FDA Clearance - TipRanks
Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg - TipRanks
ICA Group Wealth Management LLC Decreases Stock Position in Accenture plc (NYSE:ACN) - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Lifted to Strong-Buy at StockNews.com - Defense World
Aclaris Therapeutics Engages in 2024 Cantor Global Healthcare Conference - MSN
Johnson Investment Counsel Inc. Has $557,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - Defense World
Daiwa Securities Group Inc. Boosts Position in AstraZeneca PLC (NASDAQ:AZN) - Defense World
Arch Capital Group Ltd. (NASDAQ:ACGL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded by StockNews.com to "Strong-Buy" - MarketBeat
ACGL Stock Near 52-Week High: Should You Buy or Wait for a Pullback? - Zacks Investment Research
Arizona State Retirement System Purchases 1,841 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Ashton Thomas Private Wealth LLC Takes Position in AstraZeneca PLC (NASDAQ:AZN) - Defense World
Is Astrazeneca plc ADR (NASDAQ:AZN) stock a better investment at this time? - US Post News
Ratio Examination: Astrazeneca plc ADR (AZN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
AstraZeneca (NASDAQ:AZN) Upgraded by Erste Group Bank to “Buy” - Defense World
ACRS’s latest rating updates from top analysts. - Knox Daily
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewswire
Trium Capital LLP Invests $2.08 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Hair Loss Treatment Market Growth and Future Outlook Industry - openPR
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):